- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Caplin Point Laboratories Limited — Updates, 28-02-2026: Press Release
28-02-2026 | 11:57 am
28-02-2026 | 11:57 am
Caplin Point's subsidiary, Caplin Steriles, secured approval for Desmopressin Acetate Injection. This generic drug targets a US market with annual sales of approx. 215.8 Cr ($26 million), enhancing future revenue potential.
No comments yet. Be the first to comment!